Replies to post #5395 on Innovus Pharmaceuticals Inc. (fka INNV)

[erdocretire]

Reading past all the bickering I saw 2 significant
things. Multiple people say Fluticare is imminant.
Which could be true unless further review is
needed which one poster said it had been sent
back by FDA for more study. THAT is significant!
Has the FDA asked for more to study or are we
just waiting for approval?

[ShawnP123]

You make some good points but I never suggested malpractice. I just believe his tenure as CEO at Apricus was too short and he left as the stock was dropping.

The current number of shares at this stage is in excess. It will take revenue of around $30-40M with a min of 0.05 earnings/share to boost this stock. This mean, assuming 150M O/S, earnings would have to be around $7.5M. Quite frankly, I don't see that happening on the earnings side. Without Fluticare (possibly contributing $15M), this stock will be in trouble as far as pps.$15M in revenues won't cut it based on the dilution.